The following excerpts describe the upcoming
Omnipod 5 & Dexcom G7 devices.
See the article for details of other devices from
Tandem, Medtronic, Eversense, Lilly, & Abbott
(Freestyle Libre 3 which remains a mysterious
device not yet approved in the U.S. even though
it was approved in Europe in 2020):
- - -
January 5 2022 https://www.healthline.com/diabetesmine/new-diabetes-technology-in-2022
- - -
[with clarifying inserts, not part of original
article, included in brackets]
...
Omnipod 5 tubeless system
... new Omnipod 5 tubeless insulin pump system
... from ... Insulet Corp. This will be the company’s
first closed loop system that automates insulin
delivery based on CGM data.
... It connects the Omnipod tubeless patch pump
to a CGM via a smart algorithm, allowing for auto-
matic insulin dosing adjustments [i.e., basal insu-
lin adjustments based on CGM glucose levels].
It’s based on the Omnipod DASH platform ... . It
will first be available to connect with the Dexcom
CGM & later with Abbott’s FreeStyle Libre.
Omnipod 5 is also set to bring mobile app control
& insulin dosing, eliminating the need to carry a
separate Personal [Disparate High Glucose Condi-
tions] Manager (PDM) around to control the Omni-
pod.
Omnipod 5 ... had been originally planned for 2020
but was delayed because of COVID-19 & that didn’t
materialize for 2021. However, many believe it will
get FDA approval in the first half of 2022 [hmmm,
that remains to be seen, & whenever it's approved,
it's likely to be awhile after that before it's widely
available to individuals].
...
Dexcom G7
This latest model of the Dexcom CGM [currently,
Dexcom G6 is available] is set to bring a signifi-
cant form-factor change: a combined sensor &
transmitter design.
Here are the G7 details:
o Fully disposable. Unlike Dexcom CGM models to
date, the G7 will be fully disposable. ... there will no
longer be a separate transmitter with a 3-month bat-
tery life. Instead, the sensor & transmitter will be int-
egrated, and once the sensor’s run is finished, you’ll
dispose of the whole combined unit.
o Wear time. While it will start off at 10-day wear like
the current G6 version, the G7 is designed to eventu-
ally support longer wear for up to 14 to 15 days. No
fingerstick calibrations will be required, but that will
remain optional.
o Thinner. Dexcom says the G7 will be the thinnest
... of its CGM sensors yet at 60 percent smaller.
o Decision support. Dexcom has talked a lot about
wanting to integrate software features like dosing
assistance & information & prompts that help users
make better health choices based on their CGM [glu-
cose levels].
[For Omnipod 5 users, difficult to determine if that
will augment the auto-insulin pump dosages in any
helpful manner, or not]
In recent investor updates, Dexcom ... explained
that the company plans to eventually have different
versions of the G7 for different groups of users. ...
Dexcom said ... in late October 2021 it had planned
to file the G7 with the FDA in “a few weeks,” ... [the
article doesn't say the G7 has been submitted yet
& it's unknowable if the device will be widely avail-
able to end users by the end of 2022 or not].
[The after-insurance costs of the Omnipod 5 &
Dexcom G7, until they become widely available
or pricing announcements are made, difficult to
ascertain if they will be less or more expensive
than the current Omnipod & Dexcom G6 devices;
also, if one has current glucose levels < 5.6 with ...
... current devices, mysterious if the new devices
will be able to maintain those low HbA1c levels,
decrease risks from too low glucose levels, in-
crease safety & allow for fewer awakenings while
asleep to make sure glucose levels are acceptable
or are in need of insulin to lower glucose levels ...
... that are too high or glucose-raising carbs in food
or drink to respond to rapidly lowering or already-
too-low glucose levels. Ideally, the new devices
will have positive impacts on HbA1c & increased
safety & lower costs, but right now, those are mere
hopes, & only actual usage in each individual will
tell the tale.
i.e. In all the Omnipod 5 tests I've seen, very few
individuals have HbA1c < 5.6, & I can't recall see-
ing any tests of the Dexcom G7, so it's unclear
what the impact/import of those devices will be
compared to current devices (probably positive,
but impossible to know beforehand).]
~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
INSULINITIS (ISLIT)
New SUPERIOR clarifying name for near-
total to total loss of endogenous insulin https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg
The overwhelming majority of Islit caused by
autoimmune attacks on pancreatic beta cells
(Insulitis Islit) but there are
o 15 specific types of rapid onset Islit, a
rare condition (only present in < one-half
of 1% of Americans & in a much lower rate
in most of the world), when present is typ-
ically diagnosed at age under 30
(50% at age < 18, 20% at age 19 to 29)
o 1 slow onset specific type, Latent Autoim-
mune Islit, frequency unknown but per a
recent report, misdiagnosed as Cellosis
(new clarifying name for type 2 diabetes)
almost 40% of the time due to its slow
onset and its occurrence typically at age
over 30
Old outdated anachronistic name for Islit is
type 1 diabetes, confusing in that diabetes
without clarifier is often used to describe
this condition which is 1 of the 7 Disparate
High Glucose Conditions (DHGCs).
That makes figuring out which DHGC is actu-
ally being referred to (and it can be any one,
or some, or all of them when the diabetes
or diabetic word is used without clarifier)
confusing / difficult: https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg https://prohuman.net/pix2/diabetesdiabeticconfusion.jpg https://prohuman.net/pix2/diabetesdiabeticendingthemisunderstanding.jpg
- - -
It's estimated that 5% to 11% of Islit individuals
will die from severe hypoglycemia, the highest
risk of that being while sleeping (i.e., dead-in-
bed syndrome).
- - -
Shocking Misdiagnoses of Islit at All Ages https://clinical.diabetesjournals.org/content/diaclin/37/3/276/F1.large.jpg
at ages 0-6 ........ 21%
at ages 7-12 ...... 15%
at ages 13-17 .... 14%
at ages 18-29 .... 30%
at ages 30-39 .... 46%
at ages 40-49 .... 48%
50+ .................... 55%
Table showing Islit primarily misdiagnosed as
- Cellosis (new superior clarifying name for
type 2 diabetes) in adults, 76.8%
- Flu/Viral Infection in children, 53.7% https://clinical.diabetesjournals.org/highwire/markup/8771/expansion
Details on Shocking Islit Misdiagnoses &
Islit Ketoacidosis is the Leading Cause
of Death in Islit Children & Young Adults https://clinical.diabetesjournals.org/content/37/3/276
- - -
Insulin / Insulin Pump / CGM I use
Fiasp Ultra-Fast-Acting Insulin in a
tubeless Omnipod insulin pump catheter
placed into skin / pod with adhesive
stuck onto skin every 80 hours, control
via PDM (Personal Data Manager) https://prohuman.net/pix2/Fiaspinsulin_tubelessOmnipodDASHinsulinpump.jpg
Dexcom G6 CGM (continuous glucose monitor) https://prohuman.net/pix2/Dexcom_G6_CGM.jpg
- - -
Diabetes Bubble / Diabetes Bubble Burst
Outstanding! https://prohuman.net/diabetesbubblediabetesbubbleburst.htm
C.ure I.nsulinitis A.ssociation
Please! https://prohuman.net/cureinsulinitisassociation.htm
Glucose Anomalies Research regarding
Potential Cures / Improvements in Treatments
Great! https://prohuman.net/glucoseanomaliesresearch.htm
Stop Diabetes/Diabetic Confusion
with New Superior Clarifying Terms https://www.change.org/stopdiabetesdiabeticconfusionwithNewSuperiorClarifyingTerms
~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
On 1/7/2022 2:19 PM, _ wrote:
The following excerpts describe the upcoming
Omnipod 5 & Dexcom G7 devices.
See the article for details of other devices from
Tandem, Medtronic, Eversense, Lilly, & Abbott
(Freestyle Libre 3 which remains a mysterious
device not yet approved in the U.S. even though
it was approved in Europe in 2020):
- - -
January 5 2022 https://www.healthline.com/diabetesmine/new-diabetes-technology-in-2022
- - -
[with clarifying inserts, not part of original
article, included in brackets]
...
Omnipod 5 tubeless system
... new Omnipod 5 tubeless insulin pump system
... from ... Insulet Corp. This will be the company’s
first closed loop system that automates insulin
delivery based on CGM data.
... It connects the Omnipod tubeless patch pump
to a CGM via a smart algorithm, allowing for auto-
matic insulin dosing adjustments [i.e., basal insu-
lin adjustments based on CGM glucose levels].
It’s based on the Omnipod DASH platform ... . It
will first be available to connect with the Dexcom
CGM & later with Abbott’s FreeStyle Libre.
Omnipod 5 is also set to bring mobile app control
& insulin dosing, eliminating the need to carry a
separate Personal [Disparate High Glucose Condi-
tions] Manager (PDM) around to control the Omni-
pod.
Omnipod 5 ... had been originally planned for 2020
but was delayed because of COVID-19 & that didn’t
materialize for 2021. However, many believe it will
get FDA approval in the first half of 2022 [hmmm,
that remains to be seen, & whenever it's approved,
it's likely to be awhile after that before it's widely
available to individuals].
...
Dexcom G7
This latest model of the Dexcom CGM [currently,
Dexcom G6 is available] is set to bring a signifi-
cant form-factor change: a combined sensor &
transmitter design.
Here are the G7 details:
o Fully disposable. Unlike Dexcom CGM models to
date, the G7 will be fully disposable. ... there will no
longer be a separate transmitter with a 3-month bat-
tery life. Instead, the sensor & transmitter will be int-
egrated, and once the sensor’s run is finished, you’ll
dispose of the whole combined unit.
o Wear time. While it will start off at 10-day wear like
the current G6 version, the G7 is designed to eventu-
ally support longer wear for up to 14 to 15 days. No
fingerstick calibrations will be required, but that will
remain optional.
o Thinner. Dexcom says the G7 will be the thinnest
... of its CGM sensors yet at 60 percent smaller.
o Decision support. Dexcom has talked a lot about
wanting to integrate software features like dosing
assistance & information & prompts that help users
make better health choices based on their CGM [glu-
cose levels].
[For Omnipod 5 users, difficult to determine if that
will augment the auto-insulin pump dosages in any
helpful manner, or not]
In recent investor updates, Dexcom ... explained
that the company plans to eventually have different
versions of the G7 for different groups of users. ...
Dexcom said ... in late October 2021 it had planned
to file the G7 with the FDA in “a few weeks,” ... [the
article doesn't say the G7 has been submitted yet
& it's unknowable if the device will be widely avail-
able to end users by the end of 2022 or not].
[The after-insurance costs of the Omnipod 5 &
Dexcom G7, until they become widely available
or pricing announcements are made, difficult to
ascertain if they will be less or more expensive
than the current Omnipod & Dexcom G6 devices;
also, if one has current glucose levels < 5.6 with ...
... current devices, mysterious if the new devices
will be able to maintain those low HbA1c levels,
decrease risks from too low glucose levels, in-
crease safety & allow for fewer awakenings while
asleep to make sure glucose levels are acceptable
or are in need of insulin to lower glucose levels ...
... that are too high or glucose-raising carbs in food
or drink to respond to rapidly lowering or already-
too-low glucose levels. Ideally, the new devices
will have positive impacts on HbA1c & increased
safety & lower costs, but right now, those are mere
hopes, & only actual usage in each individual will
tell the tale.
i.e. In all the Omnipod 5 tests I've seen, very few
individuals have HbA1c < 5.6, & I can't recall see-
ing any tests of the Dexcom G7, so it's unclear
what the impact/import of those devices will be
compared to current devices (probably positive,
but impossible to know beforehand).]
~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
INSULINITIS (ISLIT)
New SUPERIOR clarifying name for near-
total to total loss of endogenous insulin https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg
The overwhelming majority of Islit caused by
autoimmune attacks on pancreatic beta cells
(Insulitis Islit) but there are
o 15 specific types of rapid onset Islit, a
rare condition (only present in < one-half
of 1% of Americans & in a much lower rate
in most of the world), when present is typ-
ically diagnosed at age under 30
(50% at age < 18, 20% at age 19 to 29)
o 1 slow onset specific type, Latent Autoim-
mune Islit, frequency unknown but per a
recent report, misdiagnosed as Cellosis
(new clarifying name for type 2 diabetes)
almost 40% of the time due to its slow
onset and its occurrence typically at age
over 30
Old outdated anachronistic name for Islit is
type 1 diabetes, confusing in that diabetes
without clarifier is often used to describe
this condition which is 1 of the 7 Disparate
High Glucose Conditions (DHGCs).
That makes figuring out which DHGC is actu-
ally being referred to (and it can be any one,
or some, or all of them when the diabetes
or diabetic word is used without clarifier)
confusing / difficult: https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg https://prohuman.net/pix2/diabetesdiabeticconfusion.jpg https://prohuman.net/pix2/diabetesdiabeticendingthemisunderstanding.jpg
- - -
It's estimated that 5% to 11% of Islit individuals
will die from severe hypoglycemia, the highest
risk of that being while sleeping (i.e., dead-in-
bed syndrome).
- - -
Shocking Misdiagnoses of Islit at All Ages https://clinical.diabetesjournals.org/content/diaclin/37/3/276/F1.large.jpg
at ages 0-6 ........ 21%
at ages 7-12 ...... 15%
at ages 13-17 .... 14%
at ages 18-29 .... 30%
at ages 30-39 .... 46%
at ages 40-49 .... 48%
50+ .................... 55%
Table showing Islit primarily misdiagnosed as
- Cellosis (new superior clarifying name for
type 2 diabetes) in adults, 76.8%
- Flu/Viral Infection in children, 53.7% https://clinical.diabetesjournals.org/highwire/markup/8771/expansion
Details on Shocking Islit Misdiagnoses &
Islit Ketoacidosis is the Leading Cause
of Death in Islit Children & Young Adults https://clinical.diabetesjournals.org/content/37/3/276
- - -
Insulin / Insulin Pump / CGM I use
Fiasp Ultra-Fast-Acting Insulin in a
tubeless Omnipod insulin pump catheter
placed into skin / pod with adhesive
stuck onto skin every 80 hours, control
via PDM (Personal Data Manager) https://prohuman.net/pix2/Fiaspinsulin_tubelessOmnipodDASHinsulinpump.jpg
Dexcom G6 CGM (continuous glucose monitor) https://prohuman.net/pix2/Dexcom_G6_CGM.jpg
- - -
Diabetes Bubble / Diabetes Bubble Burst
Outstanding! https://prohuman.net/diabetesbubblediabetesbubbleburst.htm
C.ure I.nsulinitis A.ssociation
Please! https://prohuman.net/cureinsulinitisassociation.htm
Glucose Anomalies Research regarding
Potential Cures / Improvements in Treatments
Great! https://prohuman.net/glucoseanomaliesresearch.htm
Stop Diabetes/Diabetic Confusion
with New Superior Clarifying Terms https://www.change.org/stopdiabetesdiabeticconfusionwithNewSuperiorClarifyingTerms
~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
On 1/7/2022 2:19 PM, _ wrote:
The following excerpts describe the upcoming
Omnipod 5 & Dexcom G7 devices.
See the article for details of other devices from
Tandem, Medtronic, Eversense, Lilly, & Abbott
(Freestyle Libre 3 which remains a mysterious
device not yet approved in the U.S. even though
it was approved in Europe in 2020):
- - -
January 5 2022 https://www.healthline.com/diabetesmine/new-diabetes-technology-in-2022
- - -
[with clarifying inserts, not part of original
article, included in brackets]
...
Omnipod 5 tubeless system
... new Omnipod 5 tubeless insulin pump system
... from ... Insulet Corp. This will be the company’s
first closed loop system that automates insulin
delivery based on CGM data.
... It connects the Omnipod tubeless patch pump
to a CGM via a smart algorithm, allowing for auto-
matic insulin dosing adjustments [i.e., basal insu-
lin adjustments based on CGM glucose levels].
It’s based on the Omnipod DASH platform ... . It
will first be available to connect with the Dexcom
CGM & later with Abbott’s FreeStyle Libre.
Omnipod 5 is also set to bring mobile app control
& insulin dosing, eliminating the need to carry a
separate Personal [Disparate High Glucose Condi-
tions] Manager (PDM) around to control the Omni-
pod.
Omnipod 5 ... had been originally planned for 2020
but was delayed because of COVID-19 & that didn’t
materialize for 2021. However, many believe it will
get FDA approval in the first half of 2022 [hmmm,
that remains to be seen, & whenever it's approved,
it's likely to be awhile after that before it's widely
available to individuals].
...
Dexcom G7
This latest model of the Dexcom CGM [currently,
Dexcom G6 is available] is set to bring a signifi-
cant form-factor change: a combined sensor &
transmitter design.
Here are the G7 details:
o Fully disposable. Unlike Dexcom CGM models to
date, the G7 will be fully disposable. ... there will no
longer be a separate transmitter with a 3-month bat-
tery life. Instead, the sensor & transmitter will be int-
egrated, and once the sensor’s run is finished, you’ll
dispose of the whole combined unit.
o Wear time. While it will start off at 10-day wear like
the current G6 version, the G7 is designed to eventu-
ally support longer wear for up to 14 to 15 days. No
fingerstick calibrations will be required, but that will
remain optional.
o Thinner. Dexcom says the G7 will be the thinnest
... of its CGM sensors yet at 60 percent smaller.
o Decision support. Dexcom has talked a lot about
wanting to integrate software features like dosing
assistance & information & prompts that help users
make better health choices based on their CGM [glu-
cose levels].
[For Omnipod 5 users, difficult to determine if that
will augment the auto-insulin pump dosages in any
helpful manner, or not]
In recent investor updates, Dexcom ... explained
that the company plans to eventually have different
versions of the G7 for different groups of users. ...
Dexcom said ... in late October 2021 it had planned
to file the G7 with the FDA in “a few weeks,” ... [the
article doesn't say the G7 has been submitted yet
& it's unknowable if the device will be widely avail-
able to end users by the end of 2022 or not].
[The after-insurance costs of the Omnipod 5 &
Dexcom G7, until they become widely available
or pricing announcements are made, difficult to
ascertain if they will be less or more expensive
than the current Omnipod & Dexcom G6 devices;
also, if one has current glucose levels < 5.6 with ...
... current devices, mysterious if the new devices
will be able to maintain those low HbA1c levels,
decrease risks from too low glucose levels, in-
crease safety & allow for fewer awakenings while
asleep to make sure glucose levels are acceptable
or are in need of insulin to lower glucose levels ...
... that are too high or glucose-raising carbs in food
or drink to respond to rapidly lowering or already-
too-low glucose levels. Ideally, the new devices
will have positive impacts on HbA1c & increased
safety & lower costs, but right now, those are mere
hopes, & only actual usage in each individual will
tell the tale.
i.e. In all the Omnipod 5 tests I've seen, very few
individuals have HbA1c < 5.6, & I can't recall see-
ing any tests of the Dexcom G7, so it's unclear
what the impact/import of those devices will be
compared to current devices (probably positive,
but impossible to know beforehand).]
~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
INSULINITIS (ISLIT)
New SUPERIOR clarifying name for near-
total to total loss of endogenous insulin https://prohuman.net/pix2/new_superior_clarifying_name_is_INSULINITIS.jpg
The overwhelming majority of Islit caused by
autoimmune attacks on pancreatic beta cells
(Insulitis Islit) but there are
o 15 specific types of rapid onset Islit, a
rare condition (only present in < one-half
of 1% of Americans & in a much lower rate
in most of the world), when present is typ-
ically diagnosed at age under 30
(50% at age < 18, 20% at age 19 to 29)
o 1 slow onset specific type, Latent Autoim-
mune Islit, frequency unknown but per a
recent report, misdiagnosed as Cellosis
(new clarifying name for type 2 diabetes)
almost 40% of the time due to its slow
onset and its occurrence typically at age
over 30
Old outdated anachronistic name for Islit is
type 1 diabetes, confusing in that diabetes
without clarifier is often used to describe
this condition which is 1 of the 7 Disparate
High Glucose Conditions (DHGCs).
That makes figuring out which DHGC is actu-
ally being referred to (and it can be any one,
or some, or all of them when the diabetes
or diabetic word is used without clarifier)
confusing / difficult: https://prohuman.net/pix2/diabetesdiabeticguessinggame.jpg https://prohuman.net/pix2/diabetesdiabeticconfusion.jpg https://prohuman.net/pix2/diabetesdiabeticendingthemisunderstanding.jpg
- - -
It's estimated that 5% to 11% of Islit individuals
will die from severe hypoglycemia, the highest
risk of that being while sleeping (i.e., dead-in-
bed syndrome).
- - -
Shocking Misdiagnoses of Islit at All Ages https://clinical.diabetesjournals.org/content/diaclin/37/3/276/F1.large.jpg
at ages 0-6 ........ 21%
at ages 7-12 ...... 15%
at ages 13-17 .... 14%
at ages 18-29 .... 30%
at ages 30-39 .... 46%
at ages 40-49 .... 48%
50+ .................... 55%
Table showing Islit primarily misdiagnosed as
- Cellosis (new superior clarifying name for
type 2 diabetes) in adults, 76.8%
- Flu/Viral Infection in children, 53.7% https://clinical.diabetesjournals.org/highwire/markup/8771/expansion
Details on Shocking Islit Misdiagnoses &
Islit Ketoacidosis is the Leading Cause
of Death in Islit Children & Young Adults https://clinical.diabetesjournals.org/content/37/3/276
- - -
Insulin / Insulin Pump / CGM I use
Fiasp Ultra-Fast-Acting Insulin in a
tubeless Omnipod insulin pump catheter
placed into skin / pod with adhesive
stuck onto skin every 80 hours, control
via PDM (Personal Data Manager) https://prohuman.net/pix2/Fiaspinsulin_tubelessOmnipodDASHinsulinpump.jpg
Dexcom G6 CGM (continuous glucose monitor) https://prohuman.net/pix2/Dexcom_G6_CGM.jpg
- - -
Diabetes Bubble / Diabetes Bubble Burst
Outstanding! https://prohuman.net/diabetesbubblediabetesbubbleburst.htm
C.ure I.nsulinitis A.ssociation
Please! https://prohuman.net/cureinsulinitisassociation.htm
Glucose Anomalies Research regarding
Potential Cures / Improvements in Treatments
Great! https://prohuman.net/glucoseanomaliesresearch.htm
Stop Diabetes/Diabetic Confusion
with New Superior Clarifying Terms https://www.change.org/stopdiabetesdiabeticconfusionwithNewSuperiorClarifyingTerms
~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~ ~~~
First off, Islit (Insulinitis, near-total to total loss of
endogenous insulin), the condition I've had for over
61 years (since age 5) requires exogenous insulin
to try to stay alive.
On 1/8/2022 1:53 PM, _ wrote:https://groups.google.com/g/misc.health.diabetes/c/8rx9Xcb8UKQ/m/NQc3qBluAwAJ
First off, Islit (Insulinitis, near-total to total loss of
endogenous insulin), the condition I've had for over
61 years (since age 5) requires exogenous insulin
to try to stay alive.
Did you read the book I mentioned, "The Diabetes Code"? It is a short
book. Read it and come back here.
Your post about "CURE", that's scientifically re-
futable.
Read the book.
Provide 1 iota of evidence
On 1/11/2022 3:25 PM, _ wrote:
Provide 1 iota of evidence
The book provides it, not me.
| Sysop: | Keyop |
|---|---|
| Location: | Huddersfield, West Yorkshire, UK |
| Users: | 376 |
| Nodes: | 16 (2 / 14) |
| Uptime: | 53:05:05 |
| Calls: | 8,041 |
| Files: | 13,037 |
| Messages: | 5,832,016 |
